Saxenda (liraglutide 3.0mg) and Wegovy (semaglutide 2.4mg) are the two FDA-approved injectable GLP-1 medications indicated specifically for chronic weight management in adults — though they're now joined by Zepbound (tirzepatide). Both come from Novo Nordisk. Both are subcutaneous injections. Both are in the GLP-1 receptor agonist class.
But they are not equally effective, and they are not the same medication. Saxenda was approved in 2014; Wegovy in 2021. In the years between, the science advanced substantially. A 2022 head-to-head trial put the efficacy difference in stark terms.
This guide explains what the clinical data shows, who each medication is right for in 2026, and what access looks like through telehealth.
The Quick Comparison
| Saxenda | Wegovy | |
|---|---|---|
| Active ingredient | Liraglutide | Semaglutide |
| Manufacturer | Novo Nordisk | Novo Nordisk |
| Mechanism | GLP-1 receptor agonist | GLP-1 receptor agonist |
| FDA-approved for | Chronic weight management (adults + adolescents 12+) | Chronic weight management (adults + adolescents 12+) |
| Approved | 2014 (adults); 2020 (adolescents) | 2021 (adults); 2022 (adolescents) |
| Dosing | Daily injection | Weekly injection |
| Maximum dose | 3.0mg/day | 2.4mg/week |
| Drug half-life | ~13 hours | ~7 days |
| Avg. weight loss (clinical trials) | ~8% body weight (SCALE) | ~15% body weight (STEP 1) |
| Head-to-head weight loss (STEP 8) | −6.4% body weight | −15.8% body weight |
| Brand list price | ~$1,300–$1,400/month | ~$1,300–$1,500/month |
| Compounded option via telehealth | Limited | Widely available ($99–$450/mo) |
| Pediatric approval (≥12) | Yes | Yes (since 2022) |
How They Work: Same Class, Different Molecules
Both Saxenda and Wegovy are GLP-1 receptor agonists — they mimic the GLP-1 hormone released naturally by the gut after eating. GLP-1 receptor activation:
- Stimulates insulin secretion in response to blood glucose
- Suppresses glucagon (which would otherwise raise blood sugar)
- Slows gastric emptying (food stays in the stomach longer, extending satiety)
- Acts on hypothalamic pathways to reduce hunger and food intake
The mechanism is the same. What differs is the molecule itself and how long it stays active in the body.
Liraglutide (Saxenda) is structurally similar to the human GLP-1 hormone but with a fatty acid attached that extends its half-life. Still, it's cleared from the body within approximately 13 hours, requiring daily injections to maintain therapeutic levels. It was first approved for type 2 diabetes as Victoza in 2010; Saxenda is a higher-dose formulation specifically for weight management.
Semaglutide (Wegovy) is a later-generation GLP-1 agonist with a longer fatty acid chain and structural modifications that extend its half-life to approximately 7 days — enabling once-weekly dosing. This longer half-life means more stable, sustained GLP-1 receptor activation over time. It was first approved for type 2 diabetes as Ozempic in 2017; Wegovy is the weight management formulation at the higher 2.4mg weekly dose.
The longer half-life and structural optimizations of semaglutide appear to contribute meaningfully to its greater efficacy compared to liraglutide, though the precise mechanistic reasons for the efficacy gap are still studied.
Clinical Evidence: What the Trials Show
Separate-Trial Data (Different Populations)
These trials enrolled different patient populations at different times, so direct comparison has limitations — but the magnitude of difference is instructive:
| Trial | Drug | Duration | Average Weight Loss |
|---|---|---|---|
| SCALE Obesity and Prediabetes | Liraglutide 3.0mg (Saxenda) | 56 weeks | −8.0% body weight (~−8.5 kg on placebo-adjusted basis) |
| STEP 1 | Semaglutide 2.4mg (Wegovy) | 68 weeks | −14.9% body weight |
The SCALE trial enrolled adults with BMI ≥30 or ≥27 with at least one weight-related comorbidity. Participants on Saxenda lost approximately 8% of body weight, versus 2.6% on placebo — a meaningful result, but substantially below Wegovy's STEP 1 outcomes.
STEP 8: The Direct Head-to-Head Trial
Published in JAMA in 2022, STEP 8 was the first randomized controlled trial to directly compare semaglutide 2.4mg (Wegovy) vs liraglutide 3.0mg (Saxenda) for weight management. This is the most clinically relevant comparison.
Results over 68 weeks:
| Outcome | Semaglutide 2.4mg | Liraglutide 3.0mg |
|---|---|---|
| Mean weight loss | −15.8% | −6.4% |
| ≥10% weight loss | 70.9% of participants | 25.6% of participants |
| ≥20% weight loss | 38.5% of participants | 2.5% of participants |
| Waist circumference reduction | −13.8 cm | −7.0 cm |
The difference is substantial. Semaglutide produced roughly 2.5x more weight loss than liraglutide in a head-to-head comparison. Nearly 40% of Wegovy patients lost 20% or more of body weight; fewer than 3% of Saxenda patients did.
For a 250-pound patient:
- Saxenda: average loss of ~16 lbs (6.4%)
- Wegovy: average loss of ~39.5 lbs (15.8%)
These are averages. Individual results vary significantly, and some patients respond better to liraglutide — but as a class comparison, the efficacy gap is consistent and meaningful.
Dosing and Administration
Saxenda: Daily Injections with Slow Escalation
Saxenda is titrated over 5 weeks to reach the full 3.0mg daily dose:
| Week | Daily Dose |
|---|---|
| 1 | 0.6mg |
| 2 | 1.2mg |
| 3 | 1.8mg |
| 4 | 2.4mg |
| 5+ | 3.0mg (maintenance) |
Daily injections are a significant practical burden. At stable dosing, Saxenda requires 365 injections per year — compared to 52 for Wegovy. Many patients find this adherence burden meaningful. Real-world data consistently shows lower persistence rates for daily versus weekly GLP-1 injectables.
Saxenda is injected subcutaneously in the abdomen, thigh, or upper arm. It comes in a pre-filled pen. The injection itself is similar to Wegovy in discomfort level — it's the frequency, not the injection, that differs.
Wegovy: Weekly Injections with 17-Week Escalation
Wegovy titrates over 17 weeks:
| Weeks | Weekly Dose |
|---|---|
| 1–4 | 0.25mg |
| 5–8 | 0.5mg |
| 9–12 | 1.0mg |
| 13–16 | 1.7mg |
| 17+ | 2.4mg (maintenance) |
The slower escalation is partly by design to minimize nausea during each dose increase. At 2.4mg weekly, Wegovy's maintenance dose delivers substantially more pharmacological exposure to GLP-1 receptors than Saxenda's daily 3.0mg — the longer half-life and pharmacokinetics drive greater receptor engagement.
Side Effects: Similar Class, Different Experience
Both medications produce the GLP-1 receptor agonist side effect profile: nausea, vomiting, diarrhea, constipation, and decreased appetite. Both carry the same serious warnings.
What's the Same
Common side effects:
- Nausea (most common; peaks during dose escalation)
- Vomiting
- Diarrhea and constipation
- Decreased appetite (intended effect)
- Fatigue, especially early in treatment
Serious warnings (both):
- Thyroid C-cell tumor risk (boxed warning based on rodent studies; not established in humans)
- Pancreatitis
- Gallbladder disease
- Diabetic retinopathy complications (in patients with existing retinopathy)
- Contraindicated in pregnancy
- Contraindicated in patients with personal or family history of medullary thyroid carcinoma or MEN 2
What's Different
Nausea frequency vs. intensity: Daily dosing with Saxenda means nausea can be present every day during the escalation period. With weekly Wegovy, nausea clusters in the 1–2 days after injection and fades. Many patients find weekly nausea easier to manage than lower-grade daily nausea.
Injection site reactions: Daily injections with Saxenda mean more frequent injection site rotation is needed to avoid local reactions (redness, bruising). Rotating sites on a daily basis requires more deliberate management than weekly rotation for Wegovy.
GI side effect rates in clinical data: STEP 8 showed comparable overall discontinuation due to adverse events between the two medications — so while the efficacy difference is large, the tolerability difference is more modest. Both are reasonably well-tolerated by most patients who persist through the escalation phase.
For practical strategies on managing GLP-1 nausea, see our side effect management guide.
Cost Comparison
| Medication | Brand List Price | Key Notes |
|---|---|---|
| Saxenda (liraglutide 3.0mg) | ~$1,300–$1,400/month | Novo Nordisk savings card may reduce cost |
| Wegovy (semaglutide 2.4mg) | ~$1,300–$1,500/month | Novo Nordisk savings card available |
| Compounded semaglutide injection | $99–$450/month via telehealth | Widely available; Wegovy's active ingredient |
| Compounded liraglutide injection | Less commonly available; varies | Some compounding pharmacies offer it |
The Compounded Semaglutide Advantage
This is where the practical cost picture changes significantly. Compounded semaglutide — the active ingredient in both Ozempic and Wegovy — is available through 15+ major GLP-1 telehealth platforms at $99–$450/month, depending on dose and provider.
Compounded liraglutide (Saxenda's active ingredient) is available through fewer platforms and is less standardized in pricing and availability.
The practical implication: If you're deciding between Saxenda and Wegovy primarily based on cost, and you're open to compounded injectable through telehealth, compounded semaglutide is likely both more effective and more affordable than brand Saxenda. This changes the cost calculus considerably compared to brand-vs-brand pricing.
See our GLP-1 provider comparison for current platform pricing and compounded semaglutide availability by state.
Insurance Coverage
Both medications require prior authorization for most insurance plans and are categorized as weight management medications, which has historically meant more limited coverage than medications for type 2 diabetes.
| Medication | Coverage Landscape |
|---|---|
| Saxenda | Coverage has been more established since 2014 approval; some plans with obesity benefit cover it |
| Wegovy | Growing coverage but still variable; many employer plans have added it; Medicare now covers it under certain conditions |
If your insurance covers Saxenda but not Wegovy, that's a legitimate reason to consider Saxenda — the efficacy difference may be offset by meaningful cost differences when one is covered and one isn't. Check your specific plan formulary; the landscape changes frequently.
Who Is Still Prescribed Saxenda?
Given the head-to-head efficacy data, Wegovy is generally preferred for most new patients starting GLP-1 therapy for weight management. But Saxenda continues to be prescribed in specific contexts:
Insurance coverage disparity: If a plan covers liraglutide but not semaglutide, Saxenda may be significantly cheaper out-of-pocket despite the efficacy difference.
Adolescent patients: Both are FDA-approved for adolescents 12 and older with obesity. Saxenda received this indication in 2020 and has more accumulated real-world data in pediatric populations. Wegovy received adolescent approval in 2022 and clinical data is accumulating, but some pediatric endocrinologists have more experience with Saxenda in younger patients.
Transitional use: Patients who had established response to Victoza (liraglutide 1.8mg for type 2 diabetes) may have already been on liraglutide, making Saxenda a natural continuation.
Prescriber experience: In practices where prescribers have extensive experience with liraglutide and limited experience with semaglutide, Saxenda may still be the primary offering — though this is becoming less common.
The Verdict: How They Stack Up in 2026
Saxenda was a meaningful advance in weight management when it launched in 2014. It remains an FDA-approved, clinically effective medication. But the evidence is unambiguous: semaglutide (Wegovy) produces approximately 2.5x more weight loss in head-to-head trials, with the same injection site, similar tolerability, and the convenience of weekly rather than daily dosing.
For new patients starting GLP-1 therapy for weight management in 2026, Wegovy or Zepbound (tirzepatide, which produces even greater weight loss than semaglutide) are generally the preferred options where access is possible. Compounded semaglutide through telehealth has made Wegovy's active ingredient accessible at $99–$450/month, removing much of the cost barrier that once made Saxenda competitive.
Saxenda's primary remaining advantages are specific insurance coverage situations, established data in adolescent populations, and prescriber familiarity in certain clinical settings.
For context on how Wegovy compares to other options in the GLP-1 landscape, see our Ozempic vs Mounjaro comparison.
Frequently Asked Questions
Does Wegovy cause more weight loss than Saxenda?
Yes — substantially more. The STEP 8 trial, a direct head-to-head comparison published in JAMA in 2022, found semaglutide 2.4mg weekly (Wegovy) produced −15.8% body weight loss versus −6.4% for liraglutide 3.0mg daily (Saxenda) over 68 weeks. That's roughly 2.5 times more weight loss with Wegovy. Both trials and real-world data consistently show semaglutide's superiority for weight management compared to liraglutide.
Is Saxenda still worth using in 2026?
Saxenda remains a clinically effective FDA-approved weight management option, and some patients are still prescribed it — particularly when insurance covers liraglutide but not semaglutide, when a prescriber has strong clinical experience with it, or for adolescent patients. However, given that Wegovy produces roughly 2.5x more weight loss in head-to-head trials, most new patients starting GLP-1 therapy for weight management would be better served by semaglutide (Wegovy) or tirzepatide (Zepbound) if access is possible.
Can I get Saxenda or Wegovy through telehealth?
Yes — both are available through GLP-1 telehealth platforms. Compounded semaglutide (Wegovy's active ingredient) is more widely accessible through telehealth at $99–$450/month. Brand-name Wegovy is also prescribable through telehealth at list prices around $1,300–$1,500/month. Saxenda can be prescribed via telehealth but generally at brand-name pricing (~$1,300–$1,400/month); compounded liraglutide for weight management is not as widely available through major platforms. Use our GLP-1 provider comparison to find current availability and pricing.
What is the difference between daily Saxenda and weekly Wegovy injections?
Saxenda (liraglutide 3.0mg) requires a daily subcutaneous injection — 365 injections per year at stable dosing. Wegovy (semaglutide 2.4mg) requires one subcutaneous injection per week — 52 injections per year. Beyond convenience, the pharmacokinetics differ: liraglutide has a shorter half-life (~13 hours) requiring daily dosing to maintain therapeutic levels, while semaglutide has a much longer half-life (~7 days) enabling once-weekly dosing. Most patients strongly prefer weekly over daily injections, and real-world adherence data generally supports better persistence with weekly GLP-1 medications.
Compare GLP-1 telehealth providers currently offering compounded semaglutide — Wegovy's active ingredient — on our provider comparison page. Filter by state, price, and monthly membership model.